MicroRNA polymorphisms as markers of risk, prognosis and treatment response in hematological malignancies

Crit Rev Oncol Hematol. 2015 Jan;93(1):1-17. doi: 10.1016/j.critrevonc.2014.08.006. Epub 2014 Sep 2.

Abstract

MicroRNA dysregulation is a common event in hematological malignancies. Apart from genomic and epigenetic alterations, miRNA networks may be disturbed by polymorphisms in the miRNA regulatory pathway (miRSNPs). In this review we provide an overview of three categories of miRSNPs: (1) SNPs in genes involved in miRNA biogenesis and processing; (2) SNPs in miRNA genes; and (3) SNPs in miRNA binding sites in target genes and discuss their potential role as markers of disease risk, prognosis and treatment response in hematological cancers. Although so far only the tip of the iceberg has been touched, studies of polymorphisms in the miRNA regulatory pathways have already provided some clues for the mechanisms of miRNA dysregulation in cancer and open new perspectives in the management of hematological malignancies.

Keywords: Diagnosis; Hematological malignancies; MiRSNP; MicroRNA; Polymorphism; Prognosis; Treatment response.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Hematologic Neoplasms / diagnosis
  • Hematologic Neoplasms / genetics*
  • Hematologic Neoplasms / therapy*
  • Humans
  • MicroRNAs / genetics*
  • Polymorphism, Single Nucleotide / genetics*
  • Prognosis
  • Risk

Substances

  • MicroRNAs